The Food and Drug Administration has approved a new drug from AstraZeneca for patients with lung cancer that has spread despite earlier treatments. Regulators approved the drug based on two studies of about 400 people that showed roughly 60 percent of patients treated with the drug had a partial or complete reduction of their tumor size.
Are you up for a challenge?
